CA2889494C - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome - Google Patents
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome Download PDFInfo
- Publication number
- CA2889494C CA2889494C CA2889494A CA2889494A CA2889494C CA 2889494 C CA2889494 C CA 2889494C CA 2889494 A CA2889494 A CA 2889494A CA 2889494 A CA2889494 A CA 2889494A CA 2889494 C CA2889494 C CA 2889494C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DQAWJRUXCWKFTB-UHFFFAOYSA-N CN1CCN(CC[n](c2c3c(Cl)c(-c4ccccc4)nn2)nc3-c2ccc3OCCc3c2)CC1 Chemical compound CN1CCN(CC[n](c2c3c(Cl)c(-c4ccccc4)nn2)nc3-c2ccc3OCCc3c2)CC1 DQAWJRUXCWKFTB-UHFFFAOYSA-N 0.000 description 1
- COQVJGWRHHOXFQ-UHFFFAOYSA-N CN1CCN(CC[n](c2nnc(-c3ccccc3)c(Cl)c22)nc2-c2ccc(C(F)(F)F)nc2)CC1 Chemical compound CN1CCN(CC[n](c2nnc(-c3ccccc3)c(Cl)c22)nc2-c2ccc(C(F)(F)F)nc2)CC1 COQVJGWRHHOXFQ-UHFFFAOYSA-N 0.000 description 1
- VXTVXHXCIVVFSB-UHFFFAOYSA-N CN1CCN(CC[n](c2nnc3-c4ccccc4)nc(-c4cc(cccc5)c5[o]4)c2c3Cl)CC1 Chemical compound CN1CCN(CC[n](c2nnc3-c4ccccc4)nc(-c4cc(cccc5)c5[o]4)c2c3Cl)CC1 VXTVXHXCIVVFSB-UHFFFAOYSA-N 0.000 description 1
- ZHKRDECTKCXCKU-UHFFFAOYSA-N CN1CCN(CC[n]2nc(-c3cc4ccccc4[nH]3)c3c2nnc(-c2ccccc2)c3Cl)CC1 Chemical compound CN1CCN(CC[n]2nc(-c3cc4ccccc4[nH]3)c3c2nnc(-c2ccccc2)c3Cl)CC1 ZHKRDECTKCXCKU-UHFFFAOYSA-N 0.000 description 1
- 0 CN1CCN(CC[n]2nc(C=CCOC)c3c(*)c(-c4ccccc4)nnc23)CC1 Chemical compound CN1CCN(CC[n]2nc(C=CCOC)c3c(*)c(-c4ccccc4)nnc23)CC1 0.000 description 1
- RWUAAAQFPVHRQN-UHFFFAOYSA-N C[n]1c(-c2n[n](CCN3CCN(C)CC3)c3nnc(-c4ccccc4)c(Cl)c23)ccc1 Chemical compound C[n]1c(-c2n[n](CCN3CCN(C)CC3)c3nnc(-c4ccccc4)c(Cl)c23)ccc1 RWUAAAQFPVHRQN-UHFFFAOYSA-N 0.000 description 1
- NVWGWCBTYOWBRO-UHFFFAOYSA-N Clc1c(-c2ccccc2)nnc2c1c(C1=CCOCC1)n[n]2CCN1CCNCC1 Chemical compound Clc1c(-c2ccccc2)nnc2c1c(C1=CCOCC1)n[n]2CCN1CCNCC1 NVWGWCBTYOWBRO-UHFFFAOYSA-N 0.000 description 1
- QKDNBSOKLXWNAR-UHFFFAOYSA-N O=C(C[n]1nc(C2=CCCC2)c2c1nnc(-c1ccccc1)c2Cl)N1CCCC1 Chemical compound O=C(C[n]1nc(C2=CCCC2)c2c1nnc(-c1ccccc1)c2Cl)N1CCCC1 QKDNBSOKLXWNAR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718611P | 2012-10-25 | 2012-10-25 | |
| US61/718,611 | 2012-10-25 | ||
| US201361775402P | 2013-03-08 | 2013-03-08 | |
| US61/775,402 | 2013-03-08 | ||
| PCT/US2013/066939 WO2014066836A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2889494A1 CA2889494A1 (en) | 2014-05-01 |
| CA2889494C true CA2889494C (en) | 2018-12-18 |
Family
ID=50545356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889494A Active CA2889494C (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2911671B1 (enExample) |
| JP (1) | JP6291502B2 (enExample) |
| AU (1) | AU2013334139B2 (enExample) |
| CA (1) | CA2889494C (enExample) |
| ES (1) | ES2687854T3 (enExample) |
| HU (1) | HUE039970T2 (enExample) |
| IL (1) | IL238288B (enExample) |
| PL (1) | PL2911671T3 (enExample) |
| WO (1) | WO2014066836A1 (enExample) |
| ZA (1) | ZA201502655B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6290910B2 (ja) * | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| WO2017045955A1 (en) * | 2015-09-14 | 2017-03-23 | Basf Se | Heterobicyclic compounds |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| WO2020161209A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
| WO2020161208A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| WO2022011091A1 (en) | 2020-07-09 | 2022-01-13 | Usher Iii Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
| WO2023139091A1 (en) * | 2022-01-19 | 2023-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Geralexin and uses thereof for the treatment of retinal degenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206723D0 (en) * | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel compounds |
| US20090306045A1 (en) * | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| CN101917999A (zh) * | 2007-11-07 | 2010-12-15 | 弗尔德里克斯制药股份有限公司 | 蛋白质运输的调节 |
| CA2834049C (en) * | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6290910B2 (ja) * | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
-
2013
- 2013-10-25 EP EP13848995.0A patent/EP2911671B1/en active Active
- 2013-10-25 ES ES13848995.0T patent/ES2687854T3/es active Active
- 2013-10-25 JP JP2015539868A patent/JP6291502B2/ja active Active
- 2013-10-25 WO PCT/US2013/066939 patent/WO2014066836A1/en not_active Ceased
- 2013-10-25 HU HUE13848995A patent/HUE039970T2/hu unknown
- 2013-10-25 CA CA2889494A patent/CA2889494C/en active Active
- 2013-10-25 PL PL13848995T patent/PL2911671T3/pl unknown
- 2013-10-25 AU AU2013334139A patent/AU2013334139B2/en active Active
-
2015
- 2015-04-14 IL IL238288A patent/IL238288B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02655A patent/ZA201502655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2911671B1 (en) | 2018-06-27 |
| HUE039970T2 (hu) | 2019-02-28 |
| IL238288A0 (en) | 2015-06-30 |
| HK1214180A1 (en) | 2016-07-22 |
| PL2911671T3 (pl) | 2018-11-30 |
| ZA201502655B (en) | 2017-11-29 |
| WO2014066836A1 (en) | 2014-05-01 |
| EP2911671A4 (en) | 2016-09-14 |
| ES2687854T3 (es) | 2018-10-29 |
| JP6291502B2 (ja) | 2018-03-14 |
| AU2013334139A1 (en) | 2015-04-30 |
| AU2013334139B2 (en) | 2017-08-03 |
| EP2911671A1 (en) | 2015-09-02 |
| JP2015535257A (ja) | 2015-12-10 |
| IL238288B (en) | 2018-04-30 |
| CA2889494A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013334139B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | |
| US9783545B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| JP7208142B2 (ja) | Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体 | |
| CA3207392A1 (en) | Cdk inhibitor | |
| CN102695710B (zh) | 三环吡唑胺衍生物 | |
| US9187464B2 (en) | TRPV4 antagonists | |
| RU2666349C2 (ru) | Новое конденсированное пиримидиновое соединение или его соль | |
| TW201726619A (zh) | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 | |
| AU2017269726B2 (en) | Tricyclic heterocylic derivatives | |
| AU2012249801B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome | |
| TWI671299B (zh) | 作為ｒｓｖ抗病毒化合物之螺脲化合物 | |
| AU2013209586A1 (en) | Substituted pyrimidine compounds and their use as SYK inhibitors | |
| JP2023539985A (ja) | 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体 | |
| US11981658B2 (en) | Substituted aminopyridine compounds as EGFR inhibitors | |
| CA2889537C (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| TW202517653A (zh) | 治療自體免疫疾病之大環 | |
| HK1214180B (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| WO2025057126A1 (ko) | Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물 | |
| HK1171742A (en) | Tricyclic pyrazol amine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150423 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |